Evidence map›Paper›PMID 35473518›Full record

ReviewCurrent stem cell research & therapy2023

Mesenchymal Stromal Cells and their EVs as Potential Leads for SARSCoV2 Treatment.

Vahid Kia, Reza Eshaghi-Gorji, Reyhaneh Nassiri Mansour, Hadi Hassannia, Elham Hasanzadeh, Mobina Gheibi, Amir Mellati, Seyed Ehsan Enderami

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current stem cell research & therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 59% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Vahid KiaDepartment of Medical Biotechnology, School of Medicine, Shahroud University of Medical Sciences, Shahroud, Iran.
Reza Eshaghi-GorjiStudent Research Committee, Mazandaran University of Medical Sciences, Sari, Iran.
Reyhaneh Nassiri MansourStudent Research Committee, Mazandaran University of Medical Sciences, Sari, Iran.
Hadi HassanniaImmunogenetics Research Center, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Elham HasanzadehDepartment of Tissue Engineering and Regenerative Medicine, School of Advanced Technologies in Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Mobina GheibiStudent Research Committee, Mazandaran University of Medical Sciences, Sari, Iran.
Amir MellatiDepartment of Tissue Engineering and Regenerative Medicine, School of Advanced Technologies in Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Seyed Ehsan EnderamiMolecular and Cell Biology Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Mazandaran University of Medical Sciences · IRShahroud University of Medical Sciences · IR

Funding

Mazandaran University of Medical Sciences 10372
6 · The paper itself

Abstract

In December 2019, a betacoronavirus was isolated from pneumonia cases in China and rapidly turned into a pandemic of COVID-19. The virus is an enveloped positive-sense ssRNA and causes a severe respiratory syndrome along with a cytokine storm, which is the main cause of most complications. Therefore, treatments that can effectively control the inflammatory reactions are necessary. Mesenchymal Stromal Cells and their EVs are well-known for their immunomodulatory effects, inflammation reduction, and regenerative potentials. These effects are exerted through paracrine secretion of various factors. Their EVs also transport various molecules such as microRNAs to other cells and affect recipient cells' behavior. Scores of research and clinical trials have indicated the therapeutic potential of EVs in various diseases. EVs also seem to be a promising approach for severe COVID-19 treatment. EVs have also been used to develop vaccines since EVs are biocompatible nanoparticles that can be easily isolated and engineered. In this review, we have focused on the use of Mesenchymal Stromal Cells and their EVs for the treatment of COVID-19, their therapeutic capabilities, and vaccine development.

Indexed as

COVID-19Mesenchymal Stem CellsCOVID-19 Drug TreatmentHumansInflammationRNA, ViralSARS-CoV-2RNA, ViralBetacoronavirusCOVID-19mesenchymal stromal cellsnanoparticlesSARS-CoV-2therapeutic capabilities

Identifiers

PMID35473518
OpenAlexW4224991904

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.